Eisai / Biogen’s Leqembi (lecanemab) gained accelerated and full FDA approval in 2023 based on positive clinical and biomarker outcomes from the Phase 3 CLARITY-AD trial. With the U.S. CMS…
The wet age-related macular degeneration (AMD) market in the United States is replete with intravitreal (IVT) therapies—including Regeneron’s Eylea, Roche / Genentech’s Lucentis and Vabysmo,…
Eisai / Biogen’s Leqembi (lecanemab) gained accelerated and full FDA approval in 2023 based on positive clinical and biomarker outcomes from the Phase 3 CLARITY-AD trial. With the U.S. CMS…
Immune checkpoint inhibitors have had a transformative impact in many oncology settings since their entry into the marketplace a little over a decade ago. Their use continues to advance into…
Antibody-drug conjugates have proven to be a versatile and effective tool in treating a wide range of tumor types, establishing the drug class as a valuable weapon against cancer. The approval of…
Attention-deficit / hyperactivity disorder (ADHD) is a common childhood disorder that can persist through adolescence and into adulthood, although diagnosis and treatment initiation can occur at…
Attention-deficit / hyperactivity disorder (ADHD) is a common childhood disorder that can persist through adolescence and into adulthood, although diagnosis and treatment initiation can occur at…
Numerous drugs from multiple drug classes are used as monotherapies and/or adjunctive therapies to treat major depressive disorder (MDD). The prominent use of generically available drugs (e.g.,…
Numerous drugs from multiple drug classes are used as monotherapies and/or adjunctive therapies to treat major depressive disorder (MDD). The prominent use of generically available drugs (e.g.,…
The age-related macular degeneration (AMD) market in the United States is unique given that market penetration of approved branded therapies—Roche / Genentech’s Lucentis, Regeneron’s Eylea,…
The age-related macular degeneration (AMD) market in the United States is unique given that market penetration of approved branded therapies—Roche / Genentech’s Lucentis, Regeneron’s Eylea,…
Disorders such as anxiety, substance use disorder, and insomnia frequently coexist with major depressive disorder (MDD) and present treatment challenges to psychiatrists and primary care…
For more than a decade, AbbVie’s Restasis was the only FDA-approved therapy for dry eye disease (DED) until the launch of Novartis’s Xiidra in 2016, followed by Restasis MultiDose, Sun…
For more than a decade, AbbVie’s Restasis was the only FDA-approved therapy for dry eye disease (DED) until the launch of Novartis’s Xiidra in 2016, followed by Restasis MultiDose, Sun…